Amneal Pharmaceuticals (AMRX) Invested Capital (2017 - 2026)

Amneal Pharmaceuticals' Invested Capital history runs 10 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Invested Capital fell 80.5% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $361.8 million, a 33.22% decrease from a year earlier, with the FY2025 full-year figure at $58.4 million, down 2.88% from the prior year.
• Invested Capital retreated to $6.2 million in Q1 2026 per AMRX's latest filing, from $58.4 million in the prior quarter.
• Across five years, Invested Capital topped out at $290.0 million in Q2 2025 and bottomed at $6.2 million in Q1 2026.
• The 5-year median for Invested Capital is $33.7 million (2024), against an average of $75.5 million.
• Across the five-year window, Invested Capital surged 640.52% in 2024 and tumbled 96.79% in 2025, its largest moves.
• Year by year, Invested Capital stood at $64.3 million in 2022, then fell by 5.02% to $61.0 million in 2023, then declined by 1.53% to $60.1 million in 2024, then slipped by 2.88% to $58.4 million in 2025, then plunged by 89.38% to $6.2 million in 2026.
• Per Business Quant, the three latest AMRX Invested Capital figures stand at $6.2 million (Q1 2026), $58.4 million (Q4 2025), and $7.2 million (Q3 2025).